208 completed, 118 recruiting, 107 terminated, 55 unknown. 593 Phase 1, 207 Phase 2.
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal CAR-T Cells Targeting AML CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-27 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-26 |
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-08-26 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-08-26 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-12-01 | 2026-10-29 |
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 53 | 2026-11-18 | 2026-08-24 |
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-11-01 | 2026-07-30 |
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 22 | 2026-11-01 | 2026-10-29 |
| A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML Biological SC-CAR.CLEC2Av1 - Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent | Phase 1 | Not yet recruiting | Seattle Children's Hospital | 20 | 2026-11-01 | 2026-10-29 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia PLM-102 - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 12 | 2026-10-01 | 2026-10-05 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Hydrochloroquinine & Decitabine With Venetoclax in AML Hydroxychloroquine, Venetoclax, Oral Decitabine/cedazuridine - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Rutgers, The State University of New Jersey | 18 | 2026-09-01 | 2026-09-10 |
| ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS ATRN-119, Decitabine - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | Washington University School of Medicine | 27 | 2026-08-31 | 2026-06-01 |
| A Study of CRD3874-SI in People With Leukemia CRD3874-SI - Acute Myeloid Leukemia, AML | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2026-06-15 | 2026-09-22 |
Showing 20 of 593. Sign in to see all of them.
Leukemia, Myeloid, Acute (593) · Myelodysplastic Syndromes (193) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (94) · Leukemia (67) · Recurrence (53) · Leukemia, Myelomonocytic, Chronic (48) · Lymphoma, Non-Hodgkin (39) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (37) · Multiple Myeloma (31) · Hematologic Neoplasms (30) · Leukemia, Biphenotypic, Acute (27) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Myeloproliferative Disorders (25) · Neoplasms (22) · Hodgkin Disease (19)
Hemic and Lymphatic Diseases (593) · Neoplasms by Histologic Type (592) · Hematologic Diseases (590) · Leukemia, Myeloid (584) · Neoplasms (571) · Leukemia (526) · Bone Marrow Diseases (225) · Pathologic Processes (151) · Pathological Conditions, Signs and Symptoms (151) · Disease Attributes (146) · Immune System Diseases (141) · Immunoproliferative Disorders (141) · Lymphoproliferative Disorders (140) · Lymphatic Diseases (137) · Leukemia, Lymphoid (114)
Cytarabine (83) · Azacitidine (75) · venetoclax (72) · fludarabine (41) · Decitabine (40) · Cyclophosphamide (31) · Daunorubicin (27) · Specimen Handling (26) · fludarabine phosphate (24) · Idarubicin (23) · Biopsy (19) · decitabine and cedazuridine drug combination (19) · Granulocyte Colony-Stimulating Factor (18) · Busulfan (15) · Gemtuzumab (14)
M.D. Anderson Cancer Center (38) · City of Hope Medical Center (16) · National Cancer Institute (NCI) (15) · Dana-Farber Cancer Institute (9) · Fred Hutchinson Cancer Center (9) · Novartis Pharmaceuticals (9) · University Health Network, Toronto (8) · St. Jude Children's Research Hospital (7) · Washington University School of Medicine (7) · H. Lee Moffitt Cancer Center and Research Institute (6) · Massachusetts General Hospital (6) · Pfizer (6) · Astellas Pharma Global Development, Inc. (5) · Hoffmann-La Roche (5) · OHSU Knight Cancer Institute (5)
United States (402) · China (59) · France (40) · Germany (37) · Spain (35) · Canada (34) · United Kingdom (27) · Italy (25) · Australia (22) · South Korea (16) · Japan (14) · Netherlands (14) · Belgium (9) · Poland (8) · Israel (7)
Courtney DiNardo, MD (5) · Richard Stone, MD (4) · Farhad Ravandi-Kashani, MD (3) · Ghayas Issa, MD (3) · Jorge Cortes, MD (3) · Musa Yilmaz (3) · Xiaowen Tang, Ph.D (3) · Abhishek Maiti, MBBS (2)
PMID 28054442, PMID 33741715, PMID 34267079, PMID 40513054, PMID 41621809, PMID 41796974, PMID 42013378, PMID 16564913, PMID 16609072, PMID 18824593, PMID 19546476, PMID 19557623, PMID 19652201, PMID 19965642, PMID 20371346, PMID 20602996, PMID 20733120, PMID 20876310, PMID 20959411, PMID 21613261, PMID 21654748, PMID 22009536, PMID 22139909, PMID 22301548, PMID 22589701, PMID 22801963, PMID 23071272, PMID 23400739, PMID 23733335, PMID 23763917, PMID 24002496, PMID 24138944, PMID 24200998, PMID 24355079, PMID 24451309, PMID 24497570, PMID 24639350, PMID 24641416, PMID 25047706, PMID 25082342, PMID 25157821, PMID 25239228, PMID 25381131, PMID 25425688, PMID 25484881, PMID 25621950, PMID 25624319, PMID 25631767, PMID 25805929, PMID 25818407
P30CA033572 (13), 2023 (6), 2018 (5), P30CA015704 (4), UM1CA186712 (4), 2016 (3), 2025 (3), P30CA006973 (3), U01CA070095 (3), 2008 (2), 2015 (2), P01CA018029 (2), P01CA078902 (2), P30CA014599 (2), P30CA016672 (2)